Sangamo Therapeutics (NASDAQ:SGMO) PT Lowered to $3.00 at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its target price trimmed by HC Wainwright from $5.00 to $3.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2023 earnings at ($0.24) EPS, FY2023 earnings at […]

Leave a Reply

Your email address will not be published.

Previous post Guggenheim Begins Coverage on Savara (NASDAQ:SVRA)
Next post TD Securities Trims Barrick Gold (NYSE:GOLD) Target Price to $22.00